Notice Number: NOT-DK-07-009
Key Dates
Release Date: March 22, 2007
Issued by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), (http://www.niddk.nih.gov)
The NIDDK has recently awarded a contract to Biomedical Research Models, Inc to establish a rodent models based testing program for therapeutic interventions close to use in clinical trials for the prevention, delay, reversal or amelioration of type 1 diabetes. The contractor has established colonies of two models of spontaneous type 1 diabetes (T1D), the BB rat and the NOD mouse, and protocols for testing agents that may prevent, slow or reverse T1D. NIDDK invites scientists to provide information regarding promising therapeutics or intervention strategies which require further testing in these models in preparation for clinical trials. The contractor is optimizing husbandry and treatment of the rodent models to allow interventions to be tested in rodent models approximating, as closely as possible, pre-diabetes in humans with evidence of autoimmunity and impaired glucose tolerance, and for reversal of diabetes at onset and prior to complete islet destruction. In addition, the contractor may be able to obtain targeted mechanistic data that could be used to support biomarker development for a clinical trial.
Scientists wishing to recommend agents for testing (“sponsors”) should provide the following information:
If selected to participate in the program, the sponsor will be involved in selecting and developing the most appropriate testing regimens. Sponsors will be involved in data analysis and in coauthoring publications. All data obtained under this program will be released to the public following completion of the study in a time frame that is determined by mutual agreement between the sponsor and the NIDDK.
It is important to emphasize that this program is not a funding opportunity and provides support solely for testing promising agents in the contractor’s facility.
Applications will be accepted at any time, but recommended target dates for expeditious review are April 30th and November 5th 2007. Requests will be reviewed for scientific merit by an NIDDK appointed special review panel. Acceptance into the program will be based on scientific merit, programmatic relevance, perceived translational potential and availability of resources. Format for application and additional information can be found by navigating from the T1D-RAID web page, (http://www.niddk.nih.gov/fund/diabetesspecialfunds/T1D-RAID/)
Inquiries
Inquiries regarding this notice may be directed to:
Guillermo Arreaza-Rubin, M.D.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |